Effects of clopidogrel added to aspirin in patients with recent lacunar stroke

New England Journal of Medicine

Volumn 367, Issue 9, 2012, Pages 817-825

  Benavente, Oscar R ^a   Hart, Robert G ^b   McClure, Leslie A ^c   Szychowski, Jeffrey M ^c   Coffey, Christopher S ^d   Pearce, Lesly A ^e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO;

ADULT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK REDUCTION; SUBDURAL HEMATOMA;

EID: 84865485153     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1204133     Document Type: Article

References (32)

1. Bogousslavsky J, Van Melle G, Regli F. The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke 1988;19:1083-92.
2. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001;32:2735-40.
3. Wolfe CD, Rudd AG, Howard R, et al. Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London Stroke Register. J Neurol Neurosurg Psychiatry 2002;72:211-6.
4. Del Brutto OH, Mosquera A, Sánchez X, Santos J, Noboa CA. Stroke subtypes among Hispanics living in Guayaquil, Ecuador: results from the Luis Vernaza Hospital Stroke Registry. Stroke 1993;24:1833-6.
5. Lavados PM, Sacks C, Prina L, et al. Incidence, 30-day case-fatality rate, and prognosis of stroke in Iquique, Chile: a 2-year community-based prospective study (PISCIS project). Lancet 2005;365:2206-15.
6. Sacco RL, Kargman DE, Zamanillo MC. Race-ethnic differences in stroke risk factors among hospitalized patients with cerebral infarction: the Northern Manhattan Stroke Study. Neurology 1995;45:659-63.
7. Saposnik G, Del Brutto OH. Stroke in South America: a systematic review of incidence, prevalence, and stroke subtypes. Stroke 2003;34:2103-7.
8. Worley KL, Lalonde DR, Kerr DR, Benavente O, Hart RG. Survey of the causes of stroke among Mexican Americans in South Texas. Tex Med 1998;94:62-7.
9. Zweifler RM, Lyden PD, Taft B, Kelly N, Rothrock JF. Impact of race and ethnicity on ischemic stroke: the University of California at San Diego Stroke Data Bank. Stroke 1995;26:245-8.
10. Boiten J, Lodder J. Prognosis for survival, handicap and recurrence of stroke in lacunar and superficial infarction. Cerebrovasc Dis 1993;3:221-6.
11. Ross GW, Petrovitch H, White LR, et al. Characterization of risk factors for vascular dementia: the Honolulu-Asia Aging Study. Neurology 1999;53:337-43.
12. Tatemichi TK, Desmond D, Paik M, et al. Clinical determinants of dementia related to stroke. Ann Neurol 1993;33:568-75.
13. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-76.
14. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78.
15. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. [Errata, N Engl J Med 2001;345:1506, 1716.]
16. Usman MHU, Notaro LA, Nagarakanti R, et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol 2009;103:1107-12.
17. Benavente OR, White C, Pearce LA, et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke 2011;6:164-75.
18. White CL, Szychowski JM, Roldan A, et al. Clinical features and racial/ethnic differences among 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. J Stroke Cerebrovasc Dis 2012 April 17 (Epub ahead of print).
19. Hazuda HP, Comeaux PJ, Stern MP, Haffner SM, Eifler CW, Rosenthal M. A comparison of three indicators for identifying Mexican Americans in epidemiologic research: methodological findings from the San Antonio Heart Study. Am J Epidemiol 1986;123:96-112.
20. McClure LA, Szychowski J, Benavente O, Coffey CS. Sample size re-estimation in an on-going NIH-sponsored clinical trial: the Secondary Prevention of Small Subcortical Stroke trial experience. Contemp Clin Trials 2012;33:1088-93.
21. Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-7.
22. Bhatt DL, Fox KA, Hacke E, et al. Clopidogrel plus aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
23. Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-51.
24. Bousser M-G, Amarenco P, Chamorro A, et al. Terutoban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011;377:2013-22. [Erratum, Lancet 2011;378:402.]
25. Wardlaw JM. What causes lacunar stroke? J Neurol Neurosurg Psychiatry 2005;76:617-9.
26. Berger PB, Bhatt DL, Fuster V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010;121:2575-83.
27. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007;177:347-51.
28. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005;36:1588-93.
29. Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 2009;150:379-86.
30. The CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-42. [Erratum, N Engl J Med 2010;363:1585.]
31. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study. Circulation 2003;108:1682-7.
32. Palacio S, Hart RG, Pearce LA, Benavente OR. Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials. Stroke 2012;43:2157-62.